HC Wainwright & Co. Reiterates Buy on IN8bio, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on IN8bio (NASDAQ:INAB) and maintained a $14 price target.

March 15, 2024 | 10:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IN8bio's stock rating was reiterated as Buy by HC Wainwright & Co. with a price target of $14.
The reiteration of a Buy rating and a maintained price target of $14 by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could lead to a positive short term impact on IN8bio's stock price. Analyst ratings, especially from well-regarded firms, often influence investor perception and can lead to price movements.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100